Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), to improve the appearance of skin laxity on the upper arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The company's Pure I ...

SAN CLEMENTE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the second quarter and first half of fiscal year 2025, for the period ended June 30, 2025, and recent business highlights. | IFRS Results | | | | --- | --- | --- | | (U.S. dollars in thousands) | | | | Q2 2025 | | Q2 2024 | | Revenue | $20,990 | $14,642 | | Gross Profit | $15,854 | $11, ...

SAN CLEMENTE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Assaf Korner, Chief Financial Officer, will provide a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York from June 3-5, 2025. Jefferies Global Healthcare ConferencePresentation Format: Corporate o ...

— First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3% — First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth — IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2025, for the period ...